miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
- PMID: 28406477
- PMCID: PMC5477590
- DOI: 10.1038/cddis.2017.172
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Erratum in
-
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.Cell Death Dis. 2017 May 25;8(5):e2825. doi: 10.1038/cddis.2017.246. Cell Death Dis. 2017. PMID: 28542140 Free PMC article.
Abstract
microRNAs were recently suggested to contribute to the pathogenesis of nonalcoholic fatty liver disease (NAFLD), a disease lacking specific pharmacological treatments. In that regard, nuclear receptors are arising as key molecular targets for the treatment of nonalcoholic steatohepatitis (NASH). Here we show that, in a typical model of NASH-associated liver damage, microRNA-21 (miR-21) ablation results in a progressive decrease in steatosis, inflammation and lipoapoptosis, with impairment of fibrosis. In a complementary fast food (FF) diet NASH model, mimicking features of the metabolic syndrome, miR-21 levels increase in both liver and muscle, concomitantly with decreased expression of peroxisome proliferator-activated receptor α (PPARα), a key miR-21 target. Strikingly, miR-21 knockout mice fed the FF diet supplemented with farnesoid X receptor (FXR) agonist obeticholic acid (OCA) display minimal steatosis, inflammation, oxidative stress and cholesterol accumulation. In addition, lipoprotein metabolism was restored, including decreased fatty acid uptake and polyunsaturation, and liver and muscle insulin sensitivity fully reinstated. Finally, the miR-21/PPARα axis was found amplified in liver and muscle biopsies, and in serum, of NAFLD patients, co-substantiating its role in the development of the metabolic syndrome. By unveiling that miR-21 abrogation, together with FXR activation by OCA, significantly improves whole body metabolic parameters in NASH, our results highlight the therapeutic potential of nuclear receptor multi-targeting therapies for NAFLD.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Comment in
-
Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.Cell Death Dis. 2018 Mar 2;9(3):354. doi: 10.1038/s41419-018-0386-3. Cell Death Dis. 2018. PMID: 29500352 Free PMC article. No abstract available.
References
-
- Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635–1648. - PubMed
-
- Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009; 25: 230–237. - PubMed
-
- Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013; 18: 282–289. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
